The House on Friday (July 24) passed 224-189 an FDA spending package that would give the agency $3.21 billion in discretionary funding, an increase of $40.8 million over fiscal 2020 funding levels, and would provide the agency authority to recall drugs. The bill passed as part of a minibus appropriations package (H.R. 7608), with three amendments calling for FDA to allocate appropriated funds to specific agency programs. Senate appropriators have yet to introduce their bill. Inside Health Policy previously...